Kytopen is an MIT startup developing platforms to accelerate the discovery and manufacturing of cell therapies. The Flowfect technology offers a scalable, non-viral solution to deliver genetic payloads to cells in order to augment their functionality. The technology also enables continuous flow genetic manipulation of cells in a platform that can be easily automated and can be used to process both small and large sample volumes. We are integrating our technology with automated liquid handling systems and developing a large volume platform for therapeutic applications. The non-viral Flowfect solution will reduce the cost and accelerate time to market for discovering and manufacturing cost effective next-generation cell and gene therapies.